According to Novanta's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 72.9209. At the end of 2022 the company had a P/E ratio of 65.3.
Year | P/E ratio | Change |
---|---|---|
2022 | 65.3 | -47.4% |
2021 | 124 | 32.35% |
2020 | 93.8 | 23.06% |
2019 | 76.2 | 75.48% |
2018 | 43.4 | -0.39% |
2017 | 43.6 | 30.86% |
2016 | 33.3 | 152.08% |
2015 | 13.2 | -161.09% |
2014 | -21.6 | -140.44% |
2013 | 53.5 | 258.47% |
2012 | 14.9 | 26.98% |
2011 | 11.8 | -102.22% |
2010 | -529 | 90093.51% |
2009 | -0.5865 | 386.71% |
2008 | -0.1205 | -100.47% |
2007 | 25.7 | 37.74% |
2006 | 18.6 | -60.08% |
2005 | 46.7 | 310.68% |
2004 | 11.4 | -105.79% |
2003 | -196 | 2079.63% |
2002 | -9.00 | -61.75% |
2001 | -23.5 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
PAVmed
PAVM | -2.75 | -103.77% | ๐บ๐ธ USA |
Philips PHG | -37.5 | -151.45% | ๐ณ๐ฑ Netherlands |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.